Relmada Therapeutics, Inc. (RLMD)

Relmada Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Oct 10, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Cap	68	16	33	26	125	105
Market Cap Growth	-35.14%	-52.18%	24.93%	-79.01%	19.50%	-7.16%
Enterprise Value	46.93	-29.22	-63.52	-122.06	-86.8	-12.4
Last Close Price	2.04	0.52	1.09	0.87	4.51	6.41
PE Ratio	-	-0.20	-0.33	-0.16	-0.63	-1.68
PB Ratio	4.58	0.44	0.38	0.19	0.60	0.99
P/TBV Ratio	3.96	0.44	0.38	0.18	0.38	0.95
P/FCF Ratio	-	-0.30	-0.64	-0.25	-1.36	-3.76
P/OCF Ratio	-	-0.30	-0.64	-0.25	-1.36	-3.76
EV/EBITDA Ratio	-	-0.35	-0.61	-0.76	-0.69	-0.20
EV/EBIT Ratio	-	-0.35	-0.61	-0.76	-0.69	-0.20
EV/FCF Ratio	-	0.56	1.23	1.18	0.94	0.45
Quick Ratio	4.02	4.36	7.90	11.94	14.08	9.30
Current Ratio	4.11	4.45	8.00	12.26	14.83	9.37
Return on Equity (ROE)	284.58%	145.27%	96.21%	94.90%	80.07%	56.24%
Return on Assets (ROA)	210.73%	117.03%	82.81%	85.72%	73.62%	51.71%
Return on Capital (ROIC)	320928.93%	257729.76%	265903.32%	510540.39%	178393.92%	29058.94%
Return on Capital Employed (ROCE)	273.84%	138.80%	91.86%	92.49%	80.10%	54.99%
Earnings Yield	-100.39%	-509.62%	-300.92%	-607.45%	-158.76%	-59.44%
FCF Yield	-73.91%	-329.85%	-157.46%	-395.26%	-73.44%	-26.56%
Buyback Yield / Dilution	0.00%	-1.57%	0.00%	-170.20%	-150.22%	-27.30%
Total Shareholder Return	-	-1.57%	0.00%	-170.20%	-150.22%	-27.30%

Updated Jun 30, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q